Salvage therapy of imatinib-resistant hypereosinophilic syndrome with PDGFRB rearrangement
Hypereosinophilic syndrome (HES) has generally been defined as a peripheral blood eosinophil count greater than 1500/mm3 and may be associated with tissue damage. Imatinib is customarily used as the first-line therapy for HES with gene abnormalities, such as PDGFRA or PDGFRB. We presented a case whe...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2016-03-01
|
| Series: | Journal of Cancer Research and Practice |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S231130061500004X |